MK-2048: Difference between revisions

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

@@ Line 13: / Line 13: @@
 ===Pharmacokinetics===
-{| class="wikitable" border="1" width="53%" style="text-align:center"
+<table style="background: cellspacing="0px"  align="" cellpadding="0px" width="50%">
-|-
+<tr>
-!  colspan="4" align="center"| Retroviral Integrase Inhibitor [[Pharmacokinetics]]<ref>A Gaur, et al. Pharmacokinetics and Safety of Once-Daily Elvitegravir in HIV-Infected Adolescents. 17th Conference on Retroviruses. Poster Number: 874.</ref><ref>doi: 10.1128/AAC.01543-07</ref>
+<td style="width:auto; vertical-align:top;border-width:0px; border-style:inset">
-|-
+<div style="height:100%; width: 100%">
-! Parameter
+{{:Retroviral Integrase Inhibitor Pharmacokinetics}}
-! [[Raltegravir]]
+</div>
-! [[Elvitegravir]]
+</td>
-! [[MK-2048]]
+</tr>
-|-
+</table>
-! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
-! 1.8
-! 2-4
-! N/A
-|-
-! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
-! 4253
-! 2070
-! N/A
-|-
-! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
-! 32
-! ~30
-! N/A
-|-
-! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
-! 83
-! N/A
-! N/A
-|-
-! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
-! 10.8
-! 7.6
-! N/A
-|-
-! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
-! 10168
-! 21200
-! N/A
-|-
-! Dosage (mg)
-! 400
-! 150
-! N/A
-|-
-! Metabolism
-! Hepatic - (UGT1A1)
-! Hepatic - (CYP3A4)
-! N/A
-|}
 ===References===